Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$7.4 - $14.44 $316,142 - $616,905
-42,722 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$12.7 - $20.68 $2.05 Million - $3.34 Million
-161,278 Reduced 79.06%
42,722 $614,000
Q1 2021

May 17, 2021

BUY
$17.0 - $29.99 $3.47 Million - $6.12 Million
204,000 New
204,000 $3.66 Million

Others Institutions Holding ADAG

About Adagene Inc.


  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $86.4M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track This Portfolio

Track Suvretta Capital Management, LLC Portfolio

Follow Suvretta Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Suvretta Capital Management, LLC with notifications on news.